Fortunately, few optometry practices have experienced close contact with a COVID-19-positive patient – and the associated rigmarole. My Sydney city practice HineSight Optometrist, however, did have this experience in early May, which triggered a rabbit-hole journey for my business on several fronts.
After spending the first 10 years of my career as a practising optometrist in Australia and the UK, I returned to Australia in 1999 and seized an opportunity at the Cornea and Contact Lens Unit (now BHVI) where I fell in love with research. I liked following protocols, discovering associations, formulating and presenting data.
When asked to write this piece on training I had to reflect on the moments in my career that led to training being such an integral part of what I do. Small things that add up over a lifetime and mould you. Partly it was luck and opportunity, having great leaders and mentors, and having a partner who was also passionate about teaching. Read more
While 71% of Australians live in metropolitan areas of Australia1, it is important to remember country people have poorer access to health services, shorter life expectancy, and up to 1.4 times the burden of disease compared to people living in major cities2.
Neuro-ophthalmology (N/O) is an interesting subspecialty because it crosses boundaries. Almost exclusively a ‘medical–type’ specialty rather than ‘surgical’, about half of its practitioners in Australia and New Zealand are neurologists and the other half are ophthalmologists.
When people ask me how on Earth I decided to be an eye doctor I have to admit my father was one. I had never intended to do what he did and I thought I had ignored all his advice. When he told me that ‘observational’ (a.k.a. ‘Phase 4’ or ‘post-marketing’) studies were needed to show that treatments identified by randomised clinical trials (RCTs) actually worked in routine clinical practice, I thought he was just trying to boost his publication list. It turns out that I was wrong about that too. Read more
Medicinal cannabis is often presented as an alternative treatment for glaucoma. Although there is evidence that cannabis lowers intraocular pressure, its role as a viable glaucoma therapy is limited by a short duration of action, psychotropic effects, and possible tachyphylaxis.
Keratoconus is common. In fact, it’s so prevalent that I see it most days I’m in the clinic. Read more